USE OF CITALOPRAM FOR THE TREATMENT OF AFFECTIVE AND ANXIETY DISORDERS: LITERATURE REVIEW AND EVALUATION OF THE EFFECTIVENESS OF DRUG PRAM IN PATIENTS WITH BORDERLINE STATES


Cite item

Full Text

Abstract

The general principles for the use of modern antidepressant drugs, data for the comparative effectiveness of various antidepressants with emphasis on selective serotonin reuptake inhibitor citalopram are presented. The article discusses the selection criteria of antidepressants in the light of the peculiarities of their metabolism, drug interactions, and suicidal risk. The results of monotherapy with citalopram (drug Pram) in patients with symptoms of generalized anxiety or social anxiety disorder are presented. The findings confirm the justification for the choice of citalopram (drug Pram) as a drug for long-term therapy due to its efficacy and high tolerability. Drug with a pronounced therapeutic effect at a dose of 20-40 mg per day is effective in major manifestations of generalized and social anxiety.

About the authors

D V Yastrebov

D Yastrebov

References

  1. Altamura AC, Pioli R, Vitto M, et al. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999;14(4):239-45.
  2. Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive illness with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000;14:3-20.
  3. Bech P, Cialdella P. Citalopram in depression: meta-analysis of intended and unintended effects. In: Fog R, ed. Selective serotonin uptake inhibitors in depression and other indications. Int Clin Psychopharmacol 1992;6(Suppl. 5):45-54.
  4. Belsher G, Costello CG. Relapse after recovery from unipolar depression: a critical review. Psychol Bull 1988;194:84-96.
  5. Briley M. Milnacipran, a well tolerated specific serotonin and norepinephrine reuptake inhibiting antidepressant. CNS Drug Reviews 1998;4(2):137-48.
  6. Cheeta S, Schifano F, Oyefeso A, et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 2004;184:41-7.
  7. Cullberg J, Wasserman D, Stefansson CG. Who commits suicide after a suicide attempt? Acta Psychiatrica Scand 1988;77:598-603.
  8. Deaths related to drug poisoning in England and Wales. 2008. Report. Statistical Bulletin, 14 p. http://www.drugfree.org.au/fileadmin/Media/Global/DGDTHS0809.pdf
  9. Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. Br J Psychiatry 2006;189:393-8.
  10. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
  11. Feighner JP, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate to severe depression. J Clin Psychiatry 1999;60:824-30.
  12. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-9.
  13. Fredman SF, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatr 2000;61:403-8.
  14. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br J Psychiatry 2000;177:292-302.
  15. Janicak P, Davis JM, Preskorn SH, et al. Principles and practice of psychopharmacotherapy (4th Ed.). 2006;750.
  16. Kyle CJ, Petersen HEH, Overo KF. Comparison of the toleability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998;8:147-53.
  17. Liebowitz M, Gelenberg A, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005;62:190-98.
  18. Lin EH, VonKorff M, Lin E, et al. The role of the primary care physician in patient's adherence to antidepressant therapy. Med Care 1995;33:67-74.
  19. Lin EHB, Katon WJ, Von Korff M, et al. Relapse of depression in primary care: rate and clinical predictors. Arch Fam Med 1998;7:443-9.
  20. Montgomery S. Milnacipran: a review. Int Clin Psychopharmacol 2003;18(Suppl. 1):S1-S9.
  21. Montgomery SA, Rasmussen JGC, Tanghoj PA. 24-week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-8.
  22. Montgomery SA, Pedersen V, Tanghoj P, et al. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo controlled studies. Int Clin Psychopharmacol 1994;9(Suppl. 1):35-40.
  23. Nierenberg AA, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995;152:1500-3.
  24. Reimherr FW, Amsterdam HD, Quitkin FM, et al. Optimal length of continuation therapy in depression:a prospective assessment during long-term treatment with fluoxetine. Am J Psychiatry 1998;155:1247-53.
  25. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;19(Suppl. 1):29-35.
  26. Simon J, Pilling S, Burbeck R, et al. Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. Br J Psychiatry 2006;189:494-501.
  27. Simon GE, VonKorff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408.
  28. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404.
  29. Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Primary Care Companio J Clin Psychiatry 2001;3:232-5.
  30. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder). JAMA 1998;280:708-13.
  31. van Vliet LM, Westenberg HGM. Pharmacotherapy of social anxiety disorder. Social anxiety disorder. Westenberg H.G.M., den Boer J.A. Amsterdam: Syn-thesis publishers 1999:157-73.
  32. Venturini F, Sung J, Nichol M. Utilization patterns of antidepressant medications in a patient population served by a primary care medical group. J Manag Care Pharm 1999;5:243-9.
  33. Wade AG, Hochstrasser B, Isaksen PM, et al. Prevention of depression recurrence with citalopram: results from a double-blind, placebo-controlled trial. 152nd Annual meeting of the American Psychiatric Association, Washington D.C. USA 1999a.
  34. Аведисова А.С., Ястребов Д.В., Дашкина Г.К. Первичная терапия социально-тревожного расстройства // Психиатрия и психофармакология. 2007. № 9. № 2.
  35. Ястребов Д.В. Симптоматика, ассоциированная с прекращением приема антидепрессантов // Психиатрия и психофармакотерапия. 2008. Т. 10. С. 51-56.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies